المؤلفون: Li, Zhongwu, Lai, Yumei, Sun, Li, Zhang, Xiaotian, Liu, Ruping, Feng, Guoshuang, Zhou, Lixin, Jia, Lin, Huang, Xiaozheng, Kang, Wang, Lin, Dongmei, Gao, Jing, Shen, Lin

المساهمون: Gao, J, Shen, L (reprint author), Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, 52 Fucheng Rd, Beijing 100142, Peoples R China., Peking Univ Canc Hosp & Inst, Dept Pathol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing 100142, Peoples R China., Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing 100142, Peoples R China., Beijing Inst Graph Commun, Beijing 102600, Peoples R China., Capital Med Univ, Beijing Childrens Hosp, Ctr Clin Epidemiol & Evidence Based Med, Beijing 100045, Peoples R China., Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, 52 Fucheng Rd, Beijing 100142, Peoples R China.

المصدر: SCI ; PubMed

مصطلحات موضوعية: PD-Ll, EBV, Gastric cancer, Prognosis, HER2, EPSTEIN-BARR-VIRUS, ANTI-PD-L1 ANTIBODY, CARCINOMA, MPDL3280A, THERAPY, GENES, CELLS

العلاقة: HUMAN PATHOLOGY.2016,55,182-189.; 1389308; http://hdl.handle.net/20.500.11897/433470Test; WOS:000381541300024

الإتاحة: https://doi.org/20.500.11897/433470Test
https://doi.org/10.1016/j.humpath.2016.05.012Test
https://hdl.handle.net/20.500.11897/433470Test

المؤلفون: Juergen Wolf, Rieke Fischer, Michael Brockmann, Thomas Zander, Julie George, Sascha Ansén, Wim Timens, Michael von Bergwelt-Baildon, Anne M. Schultheis, Erich Stoelben, Matthias Scheffler, Reinhard Buettner, Harry J.M. Groen, Andreas H. Scheel, Sven Perner, Sebastian Michels, Martin Hellmich

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Groningen Research Institute for Asthma and COPD (GRIAC)

المصدر: OncoImmunology, 5(5):1131379. Taylor & Francis Group

مصطلحات موضوعية: 0301 basic medicine, Oncology, PD-L1, medicine.medical_specialty, early stage NSCLC, DEATH-LIGAND 1, medicine.medical_treatment, Immunology, IMMUNE, MELANOMA, Pembrolizumab, Biology, medicine.disease_cause, ANTIBODY MPDL3280A, 03 medical and health sciences, 5H1, 0302 clinical medicine, TUMOR, Internal medicine, Checkpoint inhibition, medicine, Immunology and Allergy, BREAST-CANCER, Lung cancer, PEMBROLIZUMAB, non-small cell lung cancer, Original Research, genetic alterations, Melanoma, NIVOLUMAB, ADENOCARCINOMA, Immunotherapy, medicine.disease, B7-H1, 030104 developmental biology, 030220 oncology & carcinogenesis, immunohistochemistry, Cancer research, biology.protein, Adenocarcinoma, KRAS, Antibody

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4fe71ef809691242aa09ab32f1d86cfTest
https://research.rug.nl/en/publications/45183bcf-9331-4a75-bb12-06f86907305bTest

المؤلفون: Ngiow, Shin Foong, Young, Arabella, Jacquelot, Nicolas, Yamazaki, Takahiro, Enot, David, Zitvogel, Laurence, Smyth, Mark J.

مصطلحات موضوعية: Fc-Gamma-Riii, Regulatory T, Pd-1 Blockade, Nivolumab, Antibody, Checkpoints, Increases, Rejection, Mpdl3280A, Melanoma, 1306 Cancer Research, 2730 Oncology

العلاقة: orcid:0000-0001-7098-7240; 628623; 1078671; Not set

الإتاحة: https://doi.org/10.1158/0008-5472.CAN-15-1082Test
https://espace.library.uq.edu.au/view/UQ:371242Test

المؤلفون: Roche

مصطلحات موضوعية: Conditions Small Cell Lung Carcinoma, Interventions Atezolizumab MPDL3280A, an engineered anti-PD-L1 antibody, Interventions Carboplatin, Interventions Etoposide, Interventions Placebo

العلاقة: https://dx.doi.org/10.1016/j.ejca.2024.114089Test; https://dx.doi.org/10.1016/j.euo.2023.11.005Test

الإتاحة: https://doi.org/10.25934/0000740210.1016/j.ejca.2024.11408910.1016/j.euo.2023.11.005Test

المؤلفون: Roche

مصطلحات موضوعية: Conditions Carcinoma, Non-Small-Cell Lung, Interventions Atezolizumab MPDL3280A, an engineered anti-PD-L1 antibody, Interventions Bevacizumab, Interventions Carboplatin, Interventions Paclitaxel

العلاقة: https://dx.doi.org/10.1002/cac2.12512Test; https://dx.doi.org/10.1002/cncr.35242Test; https://dx.doi.org/10.21037/tlcr-23-792Test; https://dx.doi.org/10.1200/jco.2023.41.16_suppl.2032Test

الإتاحة: https://doi.org/10.25934/0000605110.1002/cac2.1251210.1002/cncr.3524210.21037/tlcr-23-79210.1200/jco.2023.41.16_suppl.2032Test

المؤلفون: Roche

مصطلحات موضوعية: Conditions Carcinoma, Non-Squamous Non-Small Cell Lung, Interventions Atezolizumab MPDL3280A, an engineered anti-PD-L1 antibody, Interventions Carboplatin, Interventions Nab-Paclitaxel, Interventions Pemetrexed

العلاقة: https://dx.doi.org/10.1002/cac2.12512Test; https://dx.doi.org/10.1002/cncr.35242Test; https://dx.doi.org/10.21037/tlcr-23-792Test; https://dx.doi.org/10.1200/jco.2023.41.16_suppl.2032Test

الإتاحة: https://doi.org/10.25934/0000605210.1002/cac2.1251210.1002/cncr.3524210.21037/tlcr-23-79210.1200/jco.2023.41.16_suppl.2032Test

المؤلفون: Roche

مصطلحات موضوعية: Conditions Renal Cell Carcinoma, Interventions Atezolizumab MPDL3280A, an engineered anti-PD-L1 antibody, Interventions Bevacizumab, Interventions Sunitinib

العلاقة: https://dx.doi.org/10.1016/j.ejca.2024.114089Test; https://dx.doi.org/10.1016/j.euo.2023.11.005Test

الإتاحة: https://doi.org/10.25934/0000599710.1016/j.ejca.2024.11408910.1016/j.euo.2023.11.005Test

المؤلفون: Roche

مصطلحات موضوعية: Conditions Squamous Non-Small Cell Lung Cancer, Interventions Atezolizumab MPDL3280A, an engineered anti-programmed death-ligand 1 anti-PD-L1 antibody, Interventions Carboplatin, Interventions Nab-Paclitaxel, Interventions Paclitaxel

العلاقة: https://dx.doi.org/10.1016/j.ejca.2024.114089Test; https://dx.doi.org/10.1016/j.euo.2023.11.005Test

الإتاحة: https://doi.org/10.25934/0000605310.1016/j.ejca.2024.11408910.1016/j.euo.2023.11.005Test

المؤلفون: Roche

مصطلحات موضوعية: Conditions Bladder Cancer, Interventions Atezolizumab MPDL3280A [TECENTRIQ], an engineered anti-PDL1 antibody, Interventions Docetaxel, Interventions Paclitaxel, Interventions Vinflunine

العلاقة: https://dx.doi.org/10.1158/1538-7445.am2024-2392Test

الإتاحة: https://doi.org/10.25934/0000559810.1158/1538-7445.am2024-2392Test

المؤلفون: Roche

مصطلحات موضوعية: Conditions Renal Cell Carcinoma, Interventions Atezolizumab MPDL3280A, an Engineered Anti-PD-L1 Antibody, Interventions Bevacizumab, Interventions Sunitinib

العلاقة: https://dx.doi.org/10.1016/j.ejca.2024.114089Test; https://dx.doi.org/10.1016/j.euo.2023.11.005Test

الإتاحة: https://doi.org/10.25934/0000559910.1016/j.ejca.2024.11408910.1016/j.euo.2023.11.005Test